Risk of optic nerve damage linked to semaglutide varies by sex and drug form

Among 31,774 cases, Wegovy is associated with a 74.89 reporting odds ratio for ischaemic optic neuropathy compared to Ozempic at 18.81.

• Ischaemic optic neuropathy (ION) is linked to GLP-1 receptor agonists, especially semaglutide.
• Men show a higher risk for ION, with a reporting odds ratio of 116.37.
• Multivariable regression indicates that Wegovy poses a greater risk for ION than Ozempic, with an adjusted odds ratio of 4.74.
• The findings suggest a potential dose-dependent safety concern that needs further investigation.

Simplified